The Pilot and Feasibility grant program at the University of Chicago's NIDDK Digestive Diseases Research Core Center (DDRCC) is designed to provide a mechanism to promote new initiatives in digestive diseases (DD)-related research. The overall objectives of this program are to support investigations which would allow the development of preliminary data sufficient for funding of a research grant by conventional mechanisms (pilot studies) or testing of an innovative hypothesis which might have important implications or yield significant results for digestive diseases-related research (feasibility studies). Both of these broad aims have been pursued in the context of research focused on maintenance of homeostasis and an understanding of the pathobiology that accompanies intestinal inflammation. In the previous renewal (2005-10), 25 P & F projects were awarded, and in the current period (2010-14), 26 were awarded. The return on investment (ROI) over the past 10 years has exceeded 25:1, in comparison to the previous period from 1995-2004 where the ROI was 20:1. The P & F program remains an important vehicle for promoting multidisciplinary collaboration and a strong supportive scientific network for the young investigators funded by this program. Track I (new) investigators are given highest priority, followed by Tract II (non-DD) and Tract III (DD, new direction) investigators. We are requesting continuing support at the level of $110,000 per year. The funds will be combined with the $50,000 per year in supplemental funding committed by the GI section, bringing the total award amount to $160,000 or $30,000-37,500 for each award depending on the number of awards selected by the External Advisory Board. With the increased award size, the P & F awards are far more attractive to potential applicants and substantial enough to improve the odds that they will be successful in obtaining independent federal and extramural funding. A key feature of the program is the multi-disciplinary nature of the submitted proposals, coming from numerous departments, programs, and institutional affiliate within the University of Chicago network including the two of the University of Chicago affiliates, Argonne National Laboratory (ANL) and Marine Biological Laboratory (MBL). This large catchment of investigator talent reflects the overall scientific diversity of the research base of the DDRCC. The P & F program has therefore made a difference for many investigators, fostered collaboration and interaction, pushed the envelope of scholarship and discovery, and is one of the jewels of our DDRCC program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK042086-29
Application #
9617245
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
29
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Lu, Lei; Claud, Erika C (2018) Intrauterine Inflammation, Epigenetics, and Microbiome Influences on Preterm Infant Health. Curr Pathobiol Rep 6:15-21
Lu, Jing; Synowiec, Sylvia; Lu, Lei et al. (2018) Microbiota influence the development of the brain and behaviors in C57BL/6J mice. PLoS One 13:e0201829
Shiloh, Ruth; Gilad, Yuval; Ber, Yaara et al. (2018) Non-canonical activation of DAPK2 by AMPK constitutes a new pathway linking metabolic stress to autophagy. Nat Commun 9:1759
Wang, Haitao; Cheng, Minying; Dsouza, Melissa et al. (2018) Soil Bacterial Diversity Is Associated with Human Population Density in Urban Greenspaces. Environ Sci Technol 52:5115-5124
Khambu, Bilon; Huda, Nazmul; Chen, Xiaoyun et al. (2018) HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers. J Clin Invest 128:2419-2435
Cason, Cori A; Dolan, Kyle T; Sharma, Gaurav et al. (2018) Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes. J Vasc Surg 68:1552-1562.e7
Christensen, B; Micic, D; Gibson, P R et al. (2018) Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 47:753-762
Peñalver Bernabé, Beatriz; Cralle, Lauren; Gilbert, Jack A (2018) Systems biology of the human microbiome. Curr Opin Biotechnol 51:146-153
Amin, Ruhul; Asplin, John; Jung, Daniel et al. (2018) Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney Int 93:1098-1107
Lu, Jing; Lu, Lei; Yu, Yueyue et al. (2018) Effects of Intestinal Microbiota on Brain Development in Humanized Gnotobiotic Mice. Sci Rep 8:5443

Showing the most recent 10 out of 697 publications